MedPath

Rusfertide Shows Promising Results in Phase 3 Trial for Polycythemia Vera Treatment

• Protagonist Therapeutics' experimental drug rusfertide achieved primary efficacy endpoints in Phase 3 trial for polycythemia vera, demonstrating successful stabilization of red blood cells.

• The successful trial results have prompted Protagonist and their partner Takeda to plan regulatory submissions in both US and European markets later this year.

• The development represents a potential new treatment option for patients with polycythemia vera, a rare blood cancer characterized by excessive red blood cell production.

Protagonist Therapeutics announced Monday that their experimental drug rusfertide has successfully met its primary efficacy endpoints in a Phase 3 clinical trial for treating polycythemia vera, marking a significant advancement in blood cancer treatment.
The clinical trial demonstrated that rusfertide effectively stabilized red blood cell levels and improved symptoms in patients with polycythemia vera, a rare blood cancer characterized by the overproduction of red blood cells. This achievement represents a crucial milestone in addressing an important unmet medical need.

Clinical Trial Success and Market Impact

The positive trial results triggered an immediate market response, with Protagonist's shares rising 9% to $39.44 in early Monday trading, reflecting investor confidence in the drug's potential. The successful outcome has positioned the company and its partner Takeda to move forward with regulatory submissions.

Regulatory Strategy and Commercial Plans

Following these encouraging results, Protagonist Therapeutics and Takeda have announced plans to submit rusfertide for regulatory approval in both the United States and Europe within the year. This dual-market submission strategy reflects the companies' confidence in their data and their commitment to making the treatment available to patients globally.

Treatment Implications

Rusfertide's success in managing polycythemia vera symptoms could represent a significant advancement in the treatment landscape for this rare blood cancer. The drug's ability to stabilize red blood cell production addresses the fundamental pathology of the disease, potentially offering patients a new therapeutic option.

Partnership Dynamics

The collaboration between Protagonist Therapeutics and Takeda combines Protagonist's innovative drug development capabilities with Takeda's global commercial expertise, positioning rusfertide for potential successful market entry following regulatory approval.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Protagonist Therapeutics' Rusfertide Shows Promise in Polycythemia Vera Treatment

Protagonist Therapeutics' rusfertide demonstrates durable hematocrit control in Phase 3 trials for polycythemia vera, reducing the need for phlebotomy.
Strategic partnerships, including collaboration with Johnson & Johnson on JNJ-2113, expand Protagonist's pipeline into psoriasis and ulcerative colitis treatments.

uniQure Receives FDA Nod for Accelerated Approval Pathway for Huntington's Disease Gene Therapy

uniQure secured FDA agreement to pursue accelerated approval for its Huntington's disease gene therapy, potentially expediting treatment availability.
The FDA's decision reflects a more flexible approach to genetic medicines for severe rare diseases under Peter Marks.

Takeda Licenses Keros Therapeutics' Elritercept for Over $1.1 Billion to Treat Blood Cancer Anemia

Takeda Pharmaceuticals has secured an exclusive licensing agreement with Keros Therapeutics for elritercept, an activin inhibitor targeting anemia in hematologic cancers.
The deal includes a $200 million upfront payment to Keros, with potential milestone payments exceeding $1.1 billion, plus tiered royalties on net sales.

FDA Approves Revuforj (revumenib) as First Menin Inhibitor for KMT2A-Rearranged Leukemia

The FDA has approved Revuforj (revumenib) as the first and only menin inhibitor for relapsed or refractory acute leukemia with KMT2A translocation in adults and children.
The approval was based on the AUGMENT-101 trial, where 21% of patients achieved complete remission with partial hematological recovery after Revuforj treatment.

FDA Approves Syndax's Revuforj (axatilimab) as First Menin Inhibitor for Relapsed/Refractory AML

The FDA has granted accelerated approval to Revuforj (axatilimab), a first-in-class menin inhibitor, for adult patients with relapsed or refractory acute myeloid leukemia (AML).
This approval targets AML patients with specific genetic mutations, offering a new treatment option for those who have not responded to or have relapsed after previous therapies.

FDA Approves Syndax's Revuforj, a First-in-Class Menin Inhibitor for Acute Leukemia

The FDA has approved Syndax Pharmaceuticals' Revuforj (revumenib) for adults and children with relapsed or refractory acute leukemia with KMT2A rearrangement.
Revuforj, a menin inhibitor, showed a complete remission or complete remission with partial hematologic recovery in 21.2% of study participants, with a median response duration of 6.4 months.

FDA Approves Syndax's Revuforj as First Menin Inhibitor for KMT2A-Rearranged Leukemia

The FDA has granted priority review and approval to Syndax Pharmaceuticals' Revuforj (revumenib) for relapsed or refractory acute leukemia with KMT2A translocations.
Revuforj is the first FDA-approved menin inhibitor, marking a significant advancement in treating this aggressive form of leukemia in patients aged one year and older.

Pimicotinib Achieves Primary Endpoint in Phase 3 Trial for Tenosynovial Giant Cell Tumor

Merck KGaA's pimicotinib demonstrated a significant objective response rate (ORR) of 54% at week 25 compared to 3.2% for placebo in the MANEUVER trial.
The CSF-1R inhibitor showed efficacy in reducing joint stiffness and pain, as measured by NRS and BPI pain scores, respectively.

Biofrontera's Ameluz Demonstrates Success in Phase III sBCC Trial, Stock Surges

Biofrontera's Ameluz-PDT therapy met the primary endpoint in a Phase III trial for superficial basal cell carcinoma (sBCC), showing significant clinical and histological clearance.
The Ameluz-PDT treatment achieved a 65.5% success rate compared to 4.8% in the placebo group, marking a substantial improvement in sBCC lesion clearance.

Acadia To Seek First-Ever FDA Approval in Rett Syndrome

Acadia Pharmaceuticals' shares increased following positive late-stage data from a Phase III study of trofinetide for Rett syndrome, indicating the drug's potential effectiveness and safety. The company plans to submit a New Drug Application by mid-2022.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy